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Background: Hepatocellular carcinoma (HCC) is characterized by widespread epidemiological and molecular
heterogeneity. Previous work showed that in the western part of North Africa, a region of low incidence of HCC,
mutations are scarce for this tumor type. As epigenetic changes are considered possible surrogates to mutations in
human cancers, we decided, thus, to characterize DNA methylation in HCC from North-African patients.
Methods: A set of 11 loci was investigated in a series of 45 tumor specimens using methylation-specific and
combined-bisulfite restriction assay PCR. Results obtained on clinical samples were subsequently validated in liver
cancer cell lines.
Results: DNA methylation at tumor suppressor loci is significantly higher in samples displaying chromosome instability.
More importantly, DNA methylation was significantly higher in Arg/Arg when compared to Pro/Pro genotype carriers
at codon 72 rs1042522 of TP53 (65% vs 20% methylated loci, p = 0.0006), a polymorphism already known to affect
somatic mutation rate in human carcinomas. In vitro experiments in cell lines indicated that enzymes controlling DNA
methylation were differentially regulated by codon 72 Arg or Pro isoforms of p53. Furthermore, the Arg72-carrying
version of p53 was shown to re-methylate DNA more rapidly than the pro-harboring isoform. Finally, Pro-carrying cell
lines were shown to be significantly more resistant to decitabine treatment (two-fold, p = 0.005).
Conclusions: Our data suggest that Arg72Pro polymorphism in a WT p53 context may act as a primary driver of
epigenetic changes in HCC. It suggests, in addition, that rs1042522 genotype may predict sensitivity to epigenetic-
targeted therapy. This model of liver tumorigenesis that associates low penetrance genetic predisposition to epigenetic
changes emerges from a region of low HCC incidence and it may, therefore, apply essentially to population living in
similar areas. Surveys on populations submitted to highly mutagenic conditions as perinatally-acquired chronic hepatitis
B or aflatoxin B1 exposure remained to be conducted to validate our observations as a general model.
Keywords: TP53, DNA methylation, Hepatocellular Carcinoma, PolymorphismBackground
Hepatocellular carcinoma (HCC), the most frequent pri-
mary liver tumor, is a malignancy affecting around 7 105
patients each year, with highest incidences measured in
Sub-Saharan Africa and Eastern Asia. HCC is now the
fifth most common malignant tumor and the third com-
mon cause of cancer-related mortality worldwide [1].
The Western North-Africa (WNA: Morocco, Algeria
and Tunisia), is considered as an area of intermediate* Correspondence: pascal.pineau@pasteur.fr
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unless otherwise stated.endemicities for chronic viral hepatitis B and C, and dis-
plays much lower incidences of HCC than both European
or African neighboring countries [2,3]. It is generally
admitted that liver tumorigenesis is a consequence of ac-
cumulation of genetic and epigenetic alterations in key
genes controlling proapoptotic or prosurvival signals.
These changes occur generally in an impaired hepatic tis-
sue undergoing a persistent viral infection and/or a cirrho-
sis, but it could be promoted also by an exposure to
mutagens such as aflatoxin B1 [4]. Several classifications
of HCC were established to differentiate tumors by focusing
on histological characteristics, gene mutations in TP53 and
Wnt pathways and hypermethylation of tumor suppressorl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Characteristics of the 45 patients analyzed
ClinicoBiological features n %
Gender Women 12 26.7
Men 33 73.3
Age mean ± SD 58.6 ± 11.6
median 60
range 28-79
Risk factors anti-HCV 26 58
HBs Ag 10 22
anti-HBc 20 44
Cirrhotic liver 38 84
Tumor diameter mean ± SD 5.1 ± 3.6
median 4
range 1-13
Point mutations TP53 9 20
β-catenin 4 9
AXIN1 0 0
Chromosome instability mean ± SD 29 ± 24
median 20
range 0-80
Chromosome instability is expressed as the fraction of chromosome arms lost
in a given samples (chromosomes 1p, 4q, 6q, 8p, 9p, 17p were analyzed).
HCV, hepatitis C virus; HBs Ag, surface antigen of hepatitis B virus; HBc,
hepatitis B virus capsid/core.
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characterized from the most instable tumors with fre-
quent TP53 and AXIN1 mutations to stable tumors
with β-catenin alterations [7]. Moreover, transcriptomics
revealed an overexpression of imprinted and mitotic cell
cycle genes within instable tumors at odds with stable
ones that show increased levels of metabolism-controlling
genes coupled to an underexpression of stress, immune
response and cell adhesion coding genes [8,9]. Epigenetic
alterations, and particularly DNA methylation, are also
suspected to represent a class of decisive events in liver
tumorigenesis. Indeed, diverse studies have been carried
out on different cohorts of HCC patients affording insight
about epigenetic changes controlling liver carcinogenesis
[10]. Hypermethylation of a set of TSG such as RASSF1,
RIZ, CDK2NA and GSTP1 is commonly reported in HCC
[11]. Such targeted silencing is generally accompanied by
a global hypomethylation affecting repetitive elements
covering the genome [12,13]. The connections between
genetic and epigenetic features mentioned above are still
poorly understood. Finally, numerous studies have been
performed to explore the association of the genetic
background of patients with an eventual individual sus-
ceptibility to HCC [14,15]. TP53 presents, at codon 72,
a functional single nucleotide polymorphism (SNP, R72P,
rs1042522) that modulates the susceptibility to several
cancers including HCC [16]. Notably, the presence of an
arginine at codon 72 is known to be associated with
higher rates of somatic TP53mutations in tumors [17].
Despite this apparent wealth of data, carcinogenesis in
specific populations such as WNA inhabitants is still
poorly understood. The WNA patients are, actually, char-
acterized by the scarcity of alterations found in HCC [2].
This situation suggests that epigenetic changes may be the
most significant changes in WNA patients. The aim of the
study was, thus, to provide an appraisal of the epigenetic
changes occurring in HCC from a WNA population.
Methylation status at 10 individual loci as well as at repeti-
tive elements (LINE-1) was assessed. Variations in DNA
methylation levels were further confronted with genetic
data including β-catenin and TP53 mutations, chromo-
somal instability (CIN) and genotypes of selected SNPs.
We found that, in HCC from WNA, somatic changes in-
cluding methylation, mutations, or CIN were primarily
conditioned by the genotype at codon 72 of TP53. The
current report represents the first description of the exist-
ing correlation between TP53 R72P and epigenetic changes
in tumors.
Results
Tumor specific patterns in HCC compared with the
corresponding non-tumorous tissues
Clinico-biological features of the HCC patients are sum-
marized in Table 1. In this study, we examined methylationpatterns of ten tumor-associated genes (RASSF1A, GSTP1,
RIZ1, SOCS1, TNFRSF10C, hTERT, NRG1, CLU, miR-203,
miR-663) and of the LINE-1 repetitive element in 45 HCC
and 17 matching non-tumor livers (see Figure 1 and
Additional file 1: Table S1). Genes were selected on the
basis of the literature as aberrantly methylated in different
human cancers including HCC [18-29].We define Methy-
lation Index (MethIndex) as the number of methylated
genes on the total number of informative loci analyzed for
a given sample (LINE-1 was excluded from the calculation
as it is constitutively methylated). miR-663 was found
unmethylated in all samples.
First, we intended to check whether there was a sig-
nificant increase of DNA methylation in tumors when
compared with non-tumorous DNA extracted from the
liver tissue of patients with HCC. The methylation pro-
files of 17 HCCs and their matching non-tumorous liver
(NTL) tissues were visualized on a heatmap produced by
unsupervised hierarchical clustering approach. Major
differences between tumors and non-tumorous DNA en-
abled clustering analysis to discriminate between sample
types (see Figure 2A). Significant differences or trends
between HCC and NTL were detectable at four loci
(SOCS1, RIZ1, TNFRSF10C, miR-203) out of the 11 ex-
amined (Figure 2B). RASSF1 locus comparison displayed
only an infra-significant P value (P = 0.083). The overall
difference between malignant and non-malignant tissues
Figure 1 Analysis of DNA methylation in WNA HCC by two PCR methods. (A) Representative Methylation-Specific PCR for 6 of the 11loci on
5 different matching pairs of hepatocellular carcinomas and non-tumorous livers. U: PCR with primers for unmethylated DNA, M: PCR with primers
detecting methylated DNA. (B) Representative examples of combined bisulfite restriction analysis (COBRA) performed on 7 pairs of hepatocellular
carcinomas and corresponding non-tumorous livers on three different loci. The smaller bands beneath the larger ones represent digested (i.e.
methylated for BstUI and unmethylated for HpHI restriction enzymes) alleles. N, noncancerous liver; T: livertumor, C: controls, C- : native DNA from
WI38 fibroblasts in culture, C+: SssI CpG methylase-treated DNA from the same cells. Ratio of undigested/digested quantified with ImageJ 1.38
Instrument software integrated (Yang et al., [75]).
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20% in HCC versus 24 ± 20% in NT, p = 0.003, Figure 2C).
Patterns of DNA methylation in HCC from WNA
We then wondered whether the methylation pattern
could distinguish different subsets of tumors in correl-
ation with previously analyzed somatic mutations, loss
of heterozygosity (LOH) or SNPs [2,30]. Unsupervised
hierarchical clustering distinguished three categories of
HCC patients: those with low MethIndex (mean ± SD =
19 ± 18%), a second group with medium MethIndex
(42 ± 12%) and a third subset with high (69 ± 11%)
MethIndex (Figure 3A). TP53 somatic mutations and
LOH at chromosome 17p (TP53 maps in 17p13.1) were
significantly associated with the high methylation indexcluster (p = 0.022 and p = 0.014). Single-locus matrix of
correlation revealed frequent significant associations be-
tween methylation occurring at RIZ1 or RASSF1 pro-
moters and presence of methylation at other loci
(Additional file 1: Table S2). Furthermore, increased
methylation of tumor suppressor genes or decreased
methylation of LINE-1 repetitive element, were associated
with higher rates of somatic changes in tumor samples.
There was a strong correlation between LINE-1 demethyl-
ation and the loss of chromosome 17p or the presence of
somatic mutations in the tumor (either at TP53 or
CTNNB1, p = 0.006, see Figure 3B). We next decided to
explore whether DNA methylation at individual loci could
be correlated with a more general form of chromosome
instability. We calculated in a previous work on the same
Figure 2 Distinct DNA methylation levels in HCC and non-tumor livers. (A) Hierarchical unsupervisedclustering and corresponding heatmap
of the methylation status in 17 WNA HCCs and the 17 matching non tumorous livers. Clustering was obtained using a 1-rank correlation distance
calculation and an average linkage on DChip software. T symbolyzes the tumor samples whereas N corresponds to the non-tumor liver counterparts.
(B) Comparison of the methylation rates as detected at the different loci in the 45 HCC and the 17 Non-tumor livers. (C) Methylation Index in HCC and
matching non-tumor liver DNA from the same patient. Lines link the dots corresponding to T and NT specimens of the same patient.
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tion targets in HCC (1p, 4q, 6q, 8p, 9p and 17p) [2]. FAL
is the number of chromosome arms showing LOH/num-
ber of informative chromosome in a given sample [31,32].
RASSF1 methylated status was significantly associated
with higher FAL values (p = 0.034, Figure 3C) as well as
isolated 17p loss (Additional file 1: Table S3). Methylation
of RIZ1 and miR-203 was positively correlated with som-
atic mutations or losses at chromosome 17p and 4q (see
Additional file 1: Table S3). Finally, we noticed a strong
influence of the SNP rs1042522 on the methylation of
WNA HCCs. The proline variant at codon 72 of TP53
gene was significantly associated with the low methyla-
tion cluster (p = 0.04, Figure 3A), and specifically with
an almost complete absence of methylation on RIZ1,
TNFRSF10C, NRG1, hTERT and miR-203. When theMethIndex was stratified according to TP53 codon 72 ge-
notypes, significant differences were even more apparent
(see Figure 3D). A very low MethIndex was associated
with Pro/Pro genotype (mean ± SD = 20.8 ± 14%) whereas
methylation was significantly higher in tumors of individ-
uals homozygous for arginine (57.1 ± 19%, P = 0.0006).
Tumors from heterozygous Arg/Pro were occupying
an intermediate position for MethIndex (39.1 ± 23%)
suggesting the existence of an allele dosage effect of
TP53 codon 72 polymorphism on the DNA methyla-
tion in HCC from WNA patients. In addition, MethIn-
dex distributions for Arg/Arg and Arg/Pro carriers
were displaying a bimodal distribution (see Figure 3D).
Methylation of SOCS1 was appearing as particularly corre-
lated with TP53 codon 72 genotype (see Additional file 1:
Table S3).
Figure 3 TP53 ARG72PRO modulates DNA methylation in WNA HCC. (A) Hierarchical clustering and corresponding heatmap of the methylation
status at 10 loci in 45 WNA HCCs. Clustering was obtained using a 1-rank correlation distance calculation and an average linkage on DChip software.
Squares indicate the presence of a somatic change or a pathogenic variant in the corresponding samples. TP53 somatic mutation (p = 0.017), LOH at
chromosome 17p (p = 0.0094) and chromosome instability (p = 0.067) are associated with the high methylation index cluster whereas Pro/Pro at codon
72 of TP53 is significantly associated (p = 0.048) with a medium or low methylation index. (B) In WNA HCC, methylation of LINE elements correlates
significantly with the presence of other somatic changes as point mutations (in TP53, CTNNB1 and AXIN1) or allelic loss at chromosome 17p where is
mapping TP53. (C) Distribution of the Fractional Allelic Loss (FAL) according to the methylation status of RASSF1. mRASSF1, methylated or
hemimethylated locus; uRASSF1, unmethylated locus. FAL was assessed on 6 chromosomes (1p, 4q, 6q, 8p, 9p, and 17p). LOH, loss of heterozygosity.
(D) Distribution of the methylation index according to the genotype at codon 72 of p53. Methylation index is calculated as the methylated fraction at
9 loci (SOCS1, RASSF1, RIZ1, GSTP1, TNFRSF10C, miR203, NRG1, CLU and TERT).
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(PBMCs) of HCC patients and controls
Predicting the propensity of individuals to undergo a
strong DNA methylation in their tumors may prove to
be useful in a perspective of future treatment by
epigenetic-targeting drugs. To determine whether it is
possible to find a correlation between the aberrant
methylation process ongoing in tumors and the DNA
methylation in circulating lymphocytes, we analyzed the
DNA extracted from peripheral lymphocytes of 25 pa-
tients with HCC and 35 patients with chronic hepatitis B
or C but without HCC. All patients were from WNA. No
significant differences were detected between patients
with or without primary liver cancer (see Additional file 2:
Figure S1A). DNA Methylation was very low in PBMCs of
HCC patients as well as in patients infected by hepatitis
viruses (Additional file 2: Figure S1B). In contrast, LINE-1
methylation remained high in both subsets of samples.
Genetic targets usually used to assess the methylation
process in tumors did not appear to be sensitive markers
reflecting the tumor DNA methylation level when they
were analyzed ectopically as in PBMC (Additional file 2:
Figure S1C).
DNMT and DNA demethylases expression levels in liver
cancer cell lines according to TP53 codon72 genotype
We decided subsequently to explore in vitro whether
p53 codon 72 Arg or Pro-encoding isoforms could be
endowed of a differential transcriptional activity, explain-
ing the rate of DNA methylation observed in vivo. For
this purpose, we analyzed eight different TP53 wild-type
HCC cell lines differing at codon 72 (Figure 4A). All
these cell lines were expressing p53 protein either at
baseline or upon induction by doxorubicin (0.2 μM/
24 h, see western-blot on Figure 4B).
TP53 encodes a transcription activator/repressor known
to modulate directly or indirectly expression levels of
many genes [33]. As the codon 72 Arg72Pro poly-
morphism is located in the transactivation domain of
the protein, we wondered whether this genetic variation
might impact the capacity of p53 to modulate expres-
sion of those genes most directly involved in DNA
methylation i.e. DNA methyltransferases and demethy-
lases [34,35]. Using qPCR, we compared the expression
of sixteen genes encoding for factors modulating DNA
methylation levels positively or negatively. Gene expres-
sion was measured after 0.5 μM doxorubicin, or 2.5 μM
decitabine or vehicle treatment for 48 h. Baseline or
post-decitabine expression of the 16 genes was not differ-
ent according to TP53 codon 72 genotypes (data not
shown). Following doxorubicin treatment, we did not ob-
serve difference for two bona fide p53-responsive genes
(p21-CDKN1A, GADD45). By contrast, DNMT3A, TET1
and TET2 expression levels were significantly higher inArg/Arg cell lines whereas in a Pro/Pro background APO-
BEC3B expression was increased (see Figure 4C). Import-
antly, TP53 expression was significantly higher in Pro/Pro
cells. These data suggest that, in case of genotoxic stress,
Arg-bearing isoforms of p53 are more efficient inducers of
enzyme controlling DNA methylation than Pro-encoding
isoforms.
Impact of TP53 codon 72 Arg/Pro on DNA methylation
levels
We next explored whether it is possible to mimic in cell
lines what we observed on DNA from North-African
HCC patients i.e. an increased DNA methylation in
presence of Arg/Arg genotype. At variance with com-
monly performed gene inactivation experiments, differ-
ences of activity between two natural variants of a fully
functional protein were predictably rather mild [36].
Furthermore, the DNA methylation status is intrinsic to
each cell line and may differ widely at baseline. We thus
decided to analyze DNA methylation and re-methylation
dynamics following treatment with drugs modifying
DNA methylation levels. Decitabine alone, doxorubicin
alone or both drugs were sequentially used. Doxorubicin,
as an intercalating agent, is known to induce DNA
breaks but early reports have shown as well its capacity
to induce DNA methylation [32]. To analyze methyla-
tion variations, we used a methylation-specific restric-
tion enzyme (MSRE)-coupled qPCR method [37,38]. A
set of seven CpG island-containing promoters (BIRC5,
CDC25C, CLU, GSTP1, NRG1, RASSF1, SOCS1) was in-
vestigated on the panel of TP53 wild-type codon 72 Arg
or Pro HCC cell lines (Additional file 3: Figure S2).
The impact of the treatment was dependent on the
compound and on the promoter analyzed. No difference
in DNA methylation level was observed after doxorubicin
or decitabine treatment alone (data not shown). How-
ever, when decitabine (5 μM/72 h) and doxorubicin
(0.25 μM/24 h) were used sequentially in a demethylation-
remethylation procedure, a frequently higher rate of DNA
methylation was observed (see Figure 5A) in presence of
codon 72 Arg forms of p53, indicating a more active kin-
etic of DNA methylation. The phenomenon was particu-
larly pronounced for genes displaying differential
methylation in vivo (GSTP1, NRG1, RASSF1, and SOCS1).
It was not observed on promoters of genes without differ-
ential methylation (CLU) or controlling cell cycle (data of
CDC25C, BIRC5 are not shown).
TP53 codon 72 polymorphism affects sensitivity to
treatment
Given the differential gene expression or DNA methyla-
tion capacity of p53 variants, the issue of a differential
sensitivity to epigenetic-targeted treatment was asked.
The eight TP53 WT cell lines were, thus, treated either
Figure 4 Impact of TP53 ARG72PRO on the expression of genes involved in DNA methylation metabolism. (A) Panel of liver cancer cell
lines wild-type for TP53 used for in vitro experiments. (B) Western-blot analysis of p53 expression (baseline and doxorubicin-induced) in the panel
of cell lines. +: indicates doxorubicin treatment, 0.2 μM/72 h. (C) qRT-PCR analysis of genes involved in DNA methylation metabolism. All cells
were treated 48 h by 0.5 μM doxorubicin. P values are obtained by ANOVA analysis.
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Figure 5 Increased DNA methylation and increased sensitivity to DNA demethylation of ARG72 carrying HCC cell lines. (A) MSRE-coupled
qPCR analysis following sequential treatment of the cells by decitabine (5 μM/72 h) and doxorubicin (0.25 μM/24 h). ARG/ARG cell lines are often more
resistant to methylation-sensitive DNA restriction than PRO/PRO cells that usually yield weaker signal in qPCR. The figure represents the outcome of
two independent experiments in triplicate. Fold is relative to decitabine-treated only DNA. (B) Cell viability analysis of Cell lines as measured by MTT
assay in different treatment conditions.
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72 h) and cell viability measured by MTT assay. No differ-
ence was observed with decitabine whereas homozygous
Arg cells were significantly more sensitive to doxorubicin
treatment (Figure 5B). Previous experiments have shown
that differential in vitro effect of codon 72 polymorphism
was essentially a kinetic-dependent phenomenon rather
than relying on a difference in nature. We thus decided to
measure the effect of decitabine at different time point
after removal of the active compound. Cells were treated
by 5 μM decitabine during 96 h and cell culture medium
was then replaced by decitabine-free medium. Cell viabil-
ity was then measured at 24 h, 48 h, 72 h, 96 h, 7 days and
10 days. No difference was observed after 24 h or 7 and
10 days of recovery (data not shown). However, significant
differences of cell viability were observed 48 h (p = 0.05,
not shown), 72 h (p = 0.01, not shown), and 96 h (p =
0.005, see Figure 5B) post-decitabine removal. In these set-
tings, Arg/Arg HCC cells were significantly less viable
than Pro/Pro. These results suggest, therefore, a more
efficient death-inducing activity of decitabine in an Arg-
bearing p53 background.
Discussion
HCC epidemiology is known to follow ethno-geographic
variations of incidence. Intriguingly, despite intermediate
endemicities for chronic viral hepatitis B and C, low inci-
dences of HCC are registered in the WNA populations
(1.2-2.3 cases/105 habitants for males, age standardized
ratio, http://globocan.iarc.fr/) [39,40]. Remarkably, in
WNA, HCC is characterized by a relative paucity of mu-
tations at common genetic targets (TP53, CTNNB1,
AXIN1), making of liver tumorigenesis in WNA a rather
mysterious process (2). Nevertheless, and despite an ap-
parently mild tumor process, HCC prognosis in WNA is
as bad as anywhere else [41,42].
To date, no survey characterizing epigenetic features
of HCC in WNA patients has been published. Our
results were in accordance with those published by
Hernandez-Vargas et al. underlining the importance of
aberrant methylation that differentially affects RASSF1,
RIZ1 and SOCS1 in tumors and non-tumorous tissues
[43]. A rather high level of methylation was observed in
four NT liver DNA (≥4 loci methyl(+), see Figure 2A).
We could not find any annotations common to the four
patients. However, we observed that their non-tumor
liver tissues tended to be more frequently non cirrhotic
(3/4 vs 5/41, p = 0 .014) and the FAL in tumors slightly
higher (38 vs 28%, ns) than in other samples of the
series. These observations might indicate that a stronger
carcinogenic process conferring a preneoplastic status to
NT liver is at work in these patients. Alternatively, it
might be the consequence of a field cancerization
process in absence of full-fledged cirrhosis [44-46].Besides, Nishida et al. have shown that DNA methyla-
tion levels are correlated with chromosomal instability,
TP53 and β-catenin mutations [47]. Our data broadly
corroborated this model, though without integrating β-
catenin, as this alteration is very infrequent in WNA
HCC. We hereby presented data refining and strengthen-
ing this model by showing a link between polymorphism
at codon 72 of TP53, somatic mutations, chromosomal
instability and DNA methylation status in HCC from
WNA patients. The preferential association of codon 72
Arg with somatic mutation of TP53 has been thoroughly
reviewed by Soussi and Wiman [17]. Likewise, the well-
known association of chromosomal instability and TP53
mutation will preferentially occur in an Arg/Arg context
[48]. Finally, it has been shown that DNA methylation is
significantly reduced in Li-Fraumeni cell lines [49]. How-
ever, to our best knowledge, a correlation between aber-
rant methylation and germline background of patients for
TP53 was never reported.
The TP53 R72P polymorphism is known to be func-
tionally relevant. The Arg variant was shown to be asso-
ciated with a better apoptotic activity compared to Pro
allele [50]. Furthermore, predisposition studies showed
that the presence of the Pro allele is commonly associ-
ated with a higher risk of cancer including HCC [30,51]
and of defects in embryonic implantation [52]. Our data
indicate that codon 72 polymorphism conditions, appar-
ently, genomic and epigenetic alterations encountered in
the tumor tissue. In the current series of HCC from
WNA patients, the Pro variant is associated with pauci-
mutated and mildly methylated tumors. On the contrary,
the presence of Arg allele requires the presence of add-
itional somatic mutations and frequent DNA hypermethy-
lation. It is well known that aging process is accompanied
by an increase of genomic methylation that progressively
decreases the expression of multiple genes [53]. Moreover,
as shown in mouse models, an excess of p53 activity is
characterized by an aging-like syndrome [54]. Finally, it
has been shown in humans that TP53 codon72 Pro car-
riers tend to live longer than Arg carriers [55]. A link be-
tween rs1042522 and constitutive DNA methylation was,
however, never evoked so far. Our results indicated con-
sistently that TP53 codon72 Arg/Pro polymorphism may,
in the North-African ethno-environmental settings, influ-
ence somatic evolution through the modulation of DNA
methylation levels. The fact that we were able to repro-
duce this situation in vitro reinforces this hypothesis. We
did not detect baseline differences of DNA methylation
between cell lines but an increased DNA methylation was
often detectable in Arg/Arg cells after decitabine-induced
demethylation and subsequent doxorubicin-induced DNA
re-methylation. Interestingly, three of the genes showing
differential methylation between Arg and Pro variants
(GSTP1, RASSF1, and SOCS1) are known to be p53
Rebbani et al. Molecular Cancer  (2015) 14:74 Page 10 of 14targets [56-58]. This situation suggests that p53 may, de-
pending on circumstances activates or methylate its target
genes. The system we developed in vitro is relatively re-
moved from physiological conditions or from a slow and
long lasting process as tumorigenesis but it suggests that
p53 controls DNA-methylation plasticity in condition of
stress. Genome wide DNA methylation studies on normal
and pathological conditions are now warranted to confirm
our data. Another intriguing feature of DNA methylation
in Arg/Arg and Arg/Pro carriers was its bimodal distribu-
tion. We were not able to correlate this feature with any
of the clinic-biological annotations at our disposal. It is,
thus, tempting to hypothesize that p53 impact on DNA
methylation could be modulated by another genetic trait.
It is, indeed, well known that DNA methylation levels in
humans are strongly influenced by polymorphisms affect-
ing genes controlling one-carbon metabolism [59,60].
Moreover other polymorphic effectors of DNA methyla-
tion, to be found in the oxidative stress pathway or among
partners acting directly in DNA methylation (eg DNMTs),
can be suspected to influence methylation levels [61-63].
Being aware that we do not provide a mechanistic
explanation to our observations, some conspicuous dif-
ferential expression affecting genes involved in DNA
methylation metabolism, particularly those of DNMT3A
(methylating) or APOBEC3B (demethylating), however,
are in keeping with the current model of DNA-
methylation metabolism [64]. It is well known that p53
entertains tight connections with the different cellular
DNA-methyltransferases. Indeed, p53 and Dnmt3A are
direct interactors as shown by co-immunoprecipitation
experiments [65,66]. In addition, and in absence of mu-
tagenic stress, p53 is known to directly inhibit DNMT1
expression by trapping Sp1 and repressive chromatin
modifiers on the promoter of the gene [67,68]. The
links between p53 and Dnmt1 are, however, far more
complex. Both proteins have been shown to physically
interact on various p53-responsive promoters (eg survi-
vin/BIRC5) leading to their inactivation through DNA
methylation as well as other chromatin modifications
[38,69]. These data and the well-described differential
activities of p53 Arg/Pro isoforms in other epigenetic-
sensitive phenomena such as cancer or ageing, make
plausible a differential activity of rs1042522 on DNA
methylation levels.
Finally, we showed a mild but significant increased abil-
ity to recover from decitabine treatment in Pro-carrying
cells than in Arg carriers. This is in line with our hypoth-
esis according to which tumorigenesis is less dependent
on DNA methylation in Pro than in Arg carriers. In
addition, and despite hitherto disappointing results in
solid tumors, our data suggested that decitabine use in a
codon 72 Arg/Arg wild-type TP53 context might signifi-
cantly improve chemotherapeutic treatment [70,71]. Thehypothesis obviously needs further confirmation but may
be considered as a potential novel application in personal-
ized treatment of cancer.
Conclusion
Our model of tumorigenesis, relying on TP53 Arg72Pro,
may hold true only in selected populations of patients.
In areas of high HCC incidence (Far East, Sub-Saharan
Africa), populations are, indeed, exposed to potent risk
factors such as perinatal infection with hepatitis B virus
or exposure to aflatoxin B1. Such conditions, known to
induce major genomic alterations in HCC, are presum-
ably dwarfing the subtle impact of rs1042522 [72]. Cases
of primary liver cancers with somatic changes depending
primarily on TP53 R72P genotype might be confined to
low incidence areas such as WNA, Middle East, Indian
sub-continent or South America. In a research field domi-
nated by clinical and biological studies undertaken on Far-
Eastern patients, our work emphasizes the necessary space
for a research conducted on alternative populations af-
fected with specific tumor processes.Such studies may
provide valuable information for the understanding of a
disease which natural history and biology remain amaz-
ingly diverse from one world region to another.
Material and methods
Tissue specimens and DNA extraction
Sixty-three liver tissues including forty five HCC and
seventeen matching corresponding non-tumorous liver
tissues were obtained from WNA patients who under-
went a liver surgery at University hospitals in Morocco
(n = 41) and Tunisia (n = 4). Clinico-pathological features
of patients are described in Table 1. In addition, PBMCs
of thirty-five patients with chronic viral hepatitis B or C
(27 HBV+ and 8 HCV+) but without tumors were col-
lected for comparative methylation analysis with 25
PBMCs samples from patients with HCCs. All samples
have been already published in previous surveys [2]. The
research was conducted with the informed consent of
the patients in accordance to the recommendations is-
sued by the conference of Helsinki. It was approved by
the Ethics Committees of the Faculty of Medicine of
Casablanca and that of the Tunisian Ministry of Health.
DNA was extracted from frozen tissues and blood sam-
ples as previously described [73].
SNP genotyping, Screening of mutations and LOH
Data of SNP in TP53 (rs1042522) were previously pub-
lished [74]. Exons 4–10 of TP53, exons 2–6 of CTNNB1,
exons 2–8 of AXIN1 were analyzed for the presence of
point mutations by PCR-sequencing as previously de-
scribed (2). Six chromosomes (1p, 4q, 6q, 8p, 9p, 17p)
considered as “hotspots” of deletions in HCC, were
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protocol previously described [72].
Sodium bisulfite treatement
PBMCs, non-tumorous and tumorous genomic DNA
samples were subjected to bisulfite treatment using Epi-
tect® Bisulfite Kit (Qiagen, Courtabœuf, France) accord-
ing to manufacturer’s instructions. WI38 cells DNA
were used as positive control of methylation after treat-
ment with 12 units SssI methyltransferase (NE Biolabs,
Ipswich, MA) in the presence of S-adenosyl-methionine
32 μM.
Methylation assessment
Methylation status was assessed for 10 loci including eight
cancer-related genes and two miRNAs coding loci, methy-
lation presence was determined by methyl-specific PCR
(MSP) for RIZ1, RASSF1, SOCS1, TERT, TNFRSF10C
and GSTP1 genes (Additional file 1: Table S4), and
using COBRA for NRG1, CLU, mir-203 and mir-663
genes (Additional file 1: Table S5). Quantification of
LINE-1 methylation was performed by COBRA as well
according to the method described previously [75]. Var-
iations in bands intensity were analyzed by densitom-
etry using a CCD camera and the GeneTools software
(Syngene, Ozyme, Saint-Quentin-en-Yvelines, France).
A 50% increase of methylated product in tumorous
DNA as compared with non-tumorous was considered
as the positive threshold. The methylation index
(MethIndex) was defined as the ratio of the number of
loci found methylated (Met(+)Loci) on the total number
of informative loci in a given sample([Met(+) +Met(−)]
Loci): Met(+)-Loci÷[Met(+) +Met(−)]Loci.
Methyl-specific PCR (MSP)
Each PCR reaction was performed in a 25 μl final vol-
ume containing 100 ng of genomic DNA, 1X PCR buf-
fer, 1.5 mM MgCl2, 200 mMdNTP, 20 pmol of each
primer, 5 units of AmpliTaq GOLD DNA polymerase
(Applied Biosystem, Saint-Aubin, France). Reactions
were subjected to 94°C for 5 min, followed by 40 cycles
at 95°C for 1 min, 50-60°C for 1 min and 72°C for 1 min
and final extension at 72°C for 7 min on a MyCycler
thermal cycler (Bio-Rad, Marnes-la-Coquette, France).
PCR products were separated on 3% agarose gels stained
with ethidium bromide (Euromedex, Souffelweyersheim,
France) as shown in Figure 1A [76-78]. All primer se-
quences are provided in Additional file 1: Table S4.
Primers used for GSTP1, RASSF1, RIZ1, and hTERT ana-
lyses have been previously published [79-81].
Combined bisulfite restriction assay (COBRA)
PCR reactions were performed as described in MSP
method with modification of Taq DNA polymerase usingPlatinium® Taq DNA Polymerase (Life Technologies, Ill-
kirch, France). A volume of 15 μl of PCR products was
then digested with suitable restriction enzymes (Fermen-
tas, Life Technologies, Illkirch, France, Additional file 1:
Table S5). PCR products were separated on 2.5% stained
agarose gels and results were determined referring to the
density of bands related to those of controls (Figure 1B).
Primers used for miR-203 and LINE1 analyses have been
previously published [12,75].
Cell cultures, western blot analysis, MTT assay
HCC derived cell lines analyzed have been described
previously [82] (Additional file 4). The cells were
cultured in DMEM (Life Technologies, Saint-Aubin,
France) supplemented with FBS (10%, Biowest, Nuaille,
France) and antibiotic-antimycotic. Cells were incu-
bated and maintained at 37°C with humified air and 5%
CO2 (Binder, Tuttlingen, Germany). Cells at 50-60%
confluence were treated for 6-96 h at various concen-
trations of doxorubicin (Selleck chemicals, Euromedex,
Souffelweyersheim, France) and/or decitabine (Fluka,
Saint-Quentin Fallavier, France). DNA, RNA, and proteins
were extracted from 6-well plates (TPP, Dominique
Dutscher, Brumath, France). Cell culture experiments
were performed at least three times. For protein analysis,
cells were washed in cold phosphate buffered saline (PBS),
lysed in Laemmli buffer as described previously and sam-
ples loaded on Criterion XT precast gels (Bio-Rad,
Marnes-la-Coquette, France) [83]. Western-blots were
carried out with a Trans-blot Turbo transfer system as
indicated by the manufacturer (Bio-Rad). Blots were
probed with primary antibody against p53 (Santa-Cruz,
CliniSciences, Nanterre, France sc-6243, 1/1000) and
vinculin (Abcam, Cambridge, UK, ab18058, 1/500) or
actin (Sigma, Saint-Quentin Fallavier, France, a2066, 1/
5000). Cell viability was measured by MTT (3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide,
Euromedex) assay after seeding in flat bottom 96-well
plates (TPP) and treatment for various time length.
Formazan crystal resulting from MTT reduction was
solubilized in acid isopropanol and absorbance mea-
sured at 570 nm on a Fluostar Omega plate reader
(BMG Labtech, Champigny/Marne, France).
Quantitative RT-PCR
Total RNA was obtained from cell culture by direct lysis
in Tri-Reagent (Sigma). One microgram of RNA was re-
verse transcribed using a high-capacity cDNA Archive
Kit (Applied Biosystems, Villebon, France) according to
the manufacturer’s specifications. Expression of 15 genes
involved in DNA methylation (DNMT3A-B-L, DNMT1)
and demethylation (TET1-3, APOBEC1, APOBEC3A-B-C-
H, AID, SMUG and TDG) processes was analyzed. Two
known p53-responsive genes (p21-CDKN1A, GADD45)
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formed in a CFX96 qPCR machine (Bio-Rad). All samples
were measured in triplicate. The PCR volume of 10 μl in-
cluded 20 ng of RT product, 1× TaqMan Universal PCR
master mix and 1 μl of pre-validated Taqman Gene Ex-
pression Assay (TaqMan FG Shelf, Applied Biosystems,
see Additional file 1: Table S6). The reactions were incu-
bated in a 96-well optical plate at 95°C for 10 min,
followed by 40 cycles of 95°C for 15 sec and 60° for 1 min.
The Ct data was determinate using default threshold set-
tings. The threshold cycle (Ct) is defined as the fractional
cycle number at which the fluorescence passes the fixed
threshold. For data analysis, gene expression values
were determined using the calculation of the relative
quantitation (RQ) of target genes normalized to a calibra-
tor corresponding to 5 normal livers. RQ calculation was
performed using the DeltaCT method with the geometric
mean of three reference genes (TRIM44, Hs00214040_m1,
HMBS; Hs00609297_m1 and LMF2; Hs00611068_m1) as
reference [84]. The three references genes were selected
among 12 constant genes arising from a previous array
analysis of 70 HCC samples and 9 normal livers to which
were applied algorithms described previously [85].
Quantitative real-time PCR on genomic DNA
QPCR coupled Methyl Sensitive Restriction Enzyme
(MSRE) reactions were carried out as described by
Melnikof et al. [37]. Genomic DNA was extracted as
described previously and quantified using NanoDrop
ND-1000 (NanoDrop, Wilmington, USA) [82]. All di-
gestions were performed with HpaII, a methylation sen-
sitive restriction enzyme. An amount of 200 ng of
genomic DNA was digested 16 h at 37°C in a final vol-
ume of 100 μl containing 10 units of HpaII or HhaI.
After incubation, each digested sample was diluted 5-
fold with sterile water and incubated at 65°C for 15 min
to inactivate the enzyme. QPCR was performed in trip-
licate on a Bio-Rad CFX-96 system (Bio-Rad) with 10 μl
of reaction mixture containing 4 ng of digested DNA,
5 μl of 2X Sso Advanced SYBR Green Supermix (Bio-
Rad) and 5 pmoles of each primer. Primers at CMYA5
gene, mapping in 5q21.1, a region non-affected by copy
number changes in HCC, were used as reference.
QPCR conditions included a denaturation step at 98°C
for 2 min followed by 40 cycles at 98°C for 5 sec and
60°C for 1 min [86]. Results were analyzed using the
CFX Manager and Precision Melt Analysis software
(Bio-Rad). Primers are provided on Additional file 1:
Table S7.
Statistical analysis
Instat software (GraphPad Software Inc, La Jolla, CA,
USA) was used for statistical analysis of the data with the
Chi-square test, Fisher’s exact test, Student’s t-test, theMann–Whitney test, ANOVA test and Kruskal-Wallis test
as appropriate. The cut-off value for significance was of
P < 0.05. All tests were two-sided.
Additional files
Additional file 1: Table S1. Functions of the genes investigated for
DNA methylations in HCC from Western North-African patients.
Table S2. Correlation matrix of the methylated loci as detected in
North-African Hepatocellular Carcinoma. Table S3. Genetic features
associated with abnormal DNA methylation in North-African Hepatocellular
Carcinoma. Table S4. Methylation-specific PCR primers. Genome locations
of primer sequences are given according to those provided by the Genome
browser gateway. (http://genome-euro.ucsc.edu/cgi-bin/hgGateway?
db=hg11&redirect=auto&source=genome.ucsc.edu). Um: amplifies
unmethylated DNA, M: amplifies methylated DNA. Table S5. COBRA assay
primers. Genome locations of primer sequences are given according to
those provided by the Genome browser gateway. (http://genome-euro.
ucsc.edu/cgi-bin/hgGateway?db=hg11&redirect=auto&source=genome.
ucsc.edu). Table S6. Taqman Gene Expression Assay (PE Applied
Biosystems). Table S7. MSRE-qPCR primers. Genome locations of primer
sequences are given according to those provided by the Genome browser
gateway (http://genome-euro.ucsc.edu/cgi-bin/hgGateway?db=hg11&
redirect=auto&source=genome.ucsc.edu).
Additional file 2: Figure S1. (A) DNA methylation levels for the loci
studied. No difference was statistically significant. (B) Methylation Index at
9 loci for DNA extracted from peripheral lymphocytes in patients with or
without primary liver cancer. (C) Non-supervised hierarchical clustering of
DNA methylation in PBMCs does not detect any difference between
patients with or without liver cancer.
Additional file 3: Figure S2. Map of six among the seven promoters
analyzed by MSRE-qPCR. Positions of primers are indicated by double
arrows. Nucleotide position of primers is defined according to transcription
Start site (↱1). Restriction sites are shown above the gene. Exons are
symbolized at the scale by rectangles. BIRC5 assay is not shown.
Additional file 4: Supplementary data.
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